Notably enough, the early results of the FOENIX-CCA2 phase II trial have been presented at the ESMO World Congress on Gastrointestinal Cancer 2020; futibatinib monotherapy reported an ORR and a DCR of 34.3% and 76.1%, respectively, in 67 CCA patients with FGFR2 fusions or other rearrangements [42,86]. Here, FGFR2 is linked to cholangiocarcinoma.